The lungs need to be deflated: Effects of glycopyrronium on lung hyperinflation in COPD patients

Multidisciplinary Respiratory Medicine

Volumn 9, Issue 1, 2014, Pages

  Sanguinetti, Claudio M ^a,b  

^a Clinica Quisisana Orthopedia   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Bronchodilators; COPD; Dyspnea; Glycopyrronium bromide; Inspiratory capacity; Lung hyperinflation

Indexed keywords

GLYCOPYRRONIUM BROMIDE; INDACATEROL; TIOTROPIUM BROMIDE;

AIRWAY OBSTRUCTION; ATELECTASIS; BREATHING RATE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; DRUG SAFETY; EXERCISE; EXERCISE TOLERANCE; EXPIRATORY RESERVE VOLUME; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HEALTH STATUS; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; LONG TERM CARE; LUNG GAS EXCHANGE; LUNG PRESSURE; LUNG VOLUME; MAXIMAL EXPIRATORY FLOW; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE END EXPIRATORY PRESSURE; PROGNOSIS; QUALITY OF LIFE; RESIDUAL VOLUME; REVIEW; TIDAL VOLUME; TOTAL LUNG CAPACITY;

EID: 84901941194     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-9-19     Document Type: Review

References (65)

1. Age.Na.S: Broncopneumopatia cronica ostruttiva. Linee guida nazionali di riferimento per la prevenzione e la terapia. Roma; 2010.
2. AIMAR, AIPO, SIMeR, SIMG: La gestione clinica integrata della BPCO; 2013. http://www.aimarnet.it.
3. GOLD: Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2014. http://www.goldcopd.org/.
4. Leith DE, Mead J: Mechanisms determining residual volume of the lungs in normal subjects. J Appl Physiol 1967, 23:221-227.
5. Flesch JD, Dine CJ: Lung volumes. Measurement, clinical use, and coding. Chest 2012, 142:506-510.
6. Bancalari E, Clausen J: Pathophysiology of changes in absolute lung volumes. Eur Respir J 1998, 12:248-258. (Pubitemid 28325686)
7. Tantucci C, Duguet A, Similowki T, Zelter M, Derenne J-P, MilicEmili J: Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998, 12:799-804. (Pubitemid 28491647)
8. Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emil J, Lisboa C: Role of inspiratory capacity on exercise tolerance in COPD patients with and without expiratory flow limitation at rest. Eur Respir J 2000, 16:269-275. (Pubitemid 30627482)
9. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR: Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 171:591-597. (Pubitemid 40365414)
10. Tantucci C, Donati P, Nicosia F, Bertella E, Redolfi S, De Vecchi M, Corda L, Grassi V, Zulli R: Inspiratory capacity predicts mortality in patients with chronic obstructive pulmonary disease. Respir Med 2008, 102:613-619.
11. Matsuo M, Hashimoto N, Usami N, Imaizumi K, Wakai K, Kawabe T, Yokoi K, Hasegawa Y: Inspiratory capacity as a preoperative assessment of patients undergoing thoracic surgery. Interact Cardiovasc Thorac Surg 2012, 14:560-564.
12. Hogg JC, Macklem PT, Thurlbeck WM: Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968, 278:1355-1360.
13. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxon HO, Parè PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653. (Pubitemid 38787999)
14. Weibel ER: Morphometry of the human lung. New York: Academic Press; 1963.
15. Milic-Emili J: Provocative hypothesis: does mechanical injury of the peripheral airways play a role in the genesis of COPD in smokers? J Chron Obstruct Pulm Dis 2004, 1:85-92.
16. Gennimata S-A, Palamidas A, Karakontaki F, Kosmas EN, Koutsoukou A, Loukides S, Koulouris NG: Pathophysiology of evolution of small airways disease to overt COPD. J Chron Obstruct PulmDis 2010, 7:269-275.
17. Tantucci C: Limitazione dei flussi. In Il volto della BPCO che cambia, Fisiologia Clinica, Volume 2. Edited by Giuntini C, Grassi V. Torino: Utet Periodici; 2001:21-27.
18. Calverley PMF, Koulouris NG: Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005, 25:186-199.
19. Mead J, Turner JM, Macklem PT, Little JB: Significance of the relationship between lung elastic recoil and maximum expiratory flow. J Appl Physiol 1967, 22:95-106.
20. Cooper CB: The connection between Chronic Obstructive Pulmonary Disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006, 119(10A):S21-S31.
21. Macklem PT: Hyperinflation. Am Rev Respir Dis 1984, 129:1-2.
22. Koulouris NG, Dimopoulou I, Valta P, Finkelstein R, Cosio MG, Milic-Emili J: Detection of expiratory flow limitation during exercise in COPD patients. J Appl Physiol 1997, 82:723-731. (Pubitemid 27123247)
23. O'Donnell DE, Sanii R, Anthonisen NR, Younes M: Effect of dynamic airway compression on breathing pattern and respiratory sensation in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1987, 135:912-918. (Pubitemid 17055523)
24. O'Donnell DE, Bertley JC, Chau LKL, Webb KA: Qualitative aspects of exertional breathlessness in chronic airflow limitation. Pathophysiologic mechanisms. Am J Respir Crit Care Med 1997, 155:109-115. (Pubitemid 27053150)
25. Yan S: Sensation of inspiratory difficulty during inspiration threshold and hyperinflation loadings. Effect of inspiratory muscle strength. Am J Respir Crit Care Med 1999, 160:1544-1549.
26. Haluszka J, Chartrand DA, Grassino AE, Milic-Emili J: Intrinsic PEEP and arterial PCO2 in stable patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1990, 141:1194-1197. (Pubitemid 20172571)
27. Johnson BD, Reddan WG, Pegelow DF, Seow KC, Dempsey JA: Flow limitation and regulation of functional residual capacity during exercise in a physically active aging population. Am Rev Respir Dis 1991, 143:960-967.
28. O'Donnel DE, Voduc N, Fitzpatrick M, Webb KA: Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004, 24:86-94. (Pubitemid 39029073)
29. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gasllego B, Celli BR: Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163: 1395-1399. (Pubitemid 32506605)
30. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999, 115:957-965. (Pubitemid 29193661)
31. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G, on behalf of Formoterol in Chronic Obstructive Pulmonary Disease I Study Group: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:778-784. (Pubitemid 32881913)
32. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224. (Pubitemid 34162820)
33. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
34. Belmonte KE: Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:297-304.
35. Celli B, ZuWallack R, Wang S, Kesten S: Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003, 124:1743-1748. (Pubitemid 37433567)
36. O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004, 23:832-840. (Pubitemid 38807355)
37. Deesomchock A, Webb KA, Forkert L, Lam Y-M, Ofir D, Jensen D, O'Donnell DE: Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. J Chron Obstruct Pulm Dis 2010, 7:428-437.
38. O'Donnell DE, Forkert L, Webb KA: Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001, 18:914-920. (Pubitemid 34092863)
39. Oga T, Nishimura K, Tsukino M, Hajiro T, Ikeda A, Izumi T: The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease: a comparison of three different exercise tests. Am J Respir Crit Care Med 2000, 161:1897-1901. (Pubitemid 30418126)
40. Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S: Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009, 22:492-496.
41. Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M, Brusasco V: Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med 2012, 106:84-90.
42. Ali-Melkkila T, Kanto J, Iisalo E: Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 1993, 37(7):633-642. (Pubitemid 23298996)
43. Buhl R, Banerji D: Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. J Chron Obstruct Pulm Dis 2012, 7:729-741.
44. Pavkov R, Mueller S, Fiebich K, Singh D, Stowasser F, Pignatelli G, Walter B, Ziegler D, Dalvi M, Dederichs J, Rietveld I: Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 2010, 26:2527-2533.
45. Beeh KM, Bejer J: The short, the long, and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010, 27: 150-159.
46. Bourbeau J, Bartlett SJ: Patient adherence in COPD. Thorax 2008, 63:831-838.
47. Vestbo J, Anderson JA, Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Knobil K, Willits LR, Jates JC, Jones PW: Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009, 64:939-943.
48. D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severeCOPD: the GLOW1 trial. Respir Res 2011, 12:156.
49. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PMA, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Molken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF, on behalf of the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469.
50. Kerwin E, Hébert J, Gallagher N, Martin C, Overend T, Alagappan VKT, Lu Y, Banerji D: Efficacy and safety of NVA237 versusplacebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012, 40:1106-1114.
51. Partridge MR, Karlsson N, Small IR: Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009, 25:2043-2048.
52. Beeh KM, Singh D, Di Scala L, Drolimann A: Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012, 7:503-513.
53. Puente-Maestu L, Villar F, de Miguel J, Stringer WW, Sanz P, Sanz ML, García de Pedro J, Martínez-Abad Y: Clinical relevance of constant power exercise duration changes in COPD. Eur Respir J 2009, 34:340-345.
54. Witek TJ Jr, Mahler DA: Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003, 21:267-272.
55. Chapman KR, Beeh K-M, Bejer J, Bateman ED, D'Urzo A, Nutbrown R, Henley M, Chen H, Overend T, D'Andrea P: A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 2014, 14:4.
56. Beeh K-M, Beier J, Donohue JF: Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res 2012, 13:52.
57. Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B, on behalf of the INDEED study investigators: Delivery characteristics and patient's handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis 2011, 6:353-363.
58. Hesselink AE, Penninx BW, Wijnhoven HA, Kriegsman DM, van Eijk JT: Determinants of an incorrect inhalation technique in patients with asthma or COPD. Scand J Prim Health Care 2001, 19(4):255-260. (Pubitemid 34032753)
59. Vincken W, Dekhuijzen PR, Barnes P, ADMIT Group: The ADMIT series - issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J 2010, 19(1):10-20.
60. Dolovich M: New propellant-free technologies under investigation. J Aerosol Med 1999, 12(Suppl 1):S9-S17.
61. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310. (Pubitemid 32804122)
62. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers J-W J, Herinqs RMC: Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med 2007, 101:1398-1405. (Pubitemid 46832237)
63. Corden ZM, Bosley CM, Rees PJ, McLellan Cochrane G: Home nebulized therapy for patients with COPD: patient compliance with treatment and its relation to quality of life. Chest 1997, 112:1278-1282. (Pubitemid 27497859)
64. Turner J, Wright E, Mendella L, Anthonisen N: Predictors of patient adherence to long-term home nebulizer therapy for COPD. The IPPB Study Group. Intermittent Positive Pressure Breathing. Chest 1995, 108:394-400.
65. Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J: Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011, 37:264-272.